secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001104659-24-106676
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026
--------------------------------------------------------------------------------

- CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.
- Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.
- Cash runway extended into Q2 2026 due to restructuring cost savings.
- BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/tm2425668d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-106676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer